Log in

CVE:VIVAvivagen Stock Price, Forecast & News

-0.02 (-4.26 %)
(As of 07/10/2020 04:00 PM ET)
Today's Range
Now: C$0.45
50-Day Range
MA: C$0.53
52-Week Range
Now: C$0.45
Volume61,000 shs
Average Volume70,971 shs
Market CapitalizationC$18.74 million
P/E RatioN/A
Dividend YieldN/A
Avivagen Inc. develops and commercializes various products to replace antibiotics in livestock feeds to optimize the health and growth of the animals by supporting the animal's own health defenses. The company offers products based on its OxC-Beta technology, such as OxC-beta Livestock, a premix for livestock feeds; and Vivamune Health Chews supplements for companion animals. The company was formerly known as Chemaphor, Inc. and changed its name to Avivagen Inc.in May 2012. The company is headquartered in Ottawa, Canada.
Read More

Beat the Market (BTM) Rank

Analyst Opinion: 0.0Community Rank: 2.5Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

0.50 out of 5 stars

Industry, Sector and Symbol

Industry Drug Manufacturers - Major



Sales & Book Value

Annual SalesC$628,772.00
Cash FlowC$0.03 per share
Book ValueC($0.07) per share



Market CapC$18.74 million
Next Earnings Date9/4/2020 (Estimated)

Receive VIV News and Ratings via Email

Sign-up to receive the latest news and ratings for VIV and its competitors with MarketBeat's FREE daily newsletter.

Avivagen (CVE:VIV) Frequently Asked Questions

How has Avivagen's stock been impacted by COVID-19 (Coronavirus)?

Avivagen's stock was trading at C$0.60 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization. Since then, VIV shares have decreased by 25.0% and is now trading at C$0.45. View which stocks have been most impacted by Coronavirus.

When is Avivagen's next earnings date?

Avivagen is scheduled to release its next quarterly earnings announcement on Friday, September 4th 2020. View our earnings forecast for Avivagen.

Has Avivagen been receiving favorable news coverage?

News coverage about VIV stock has been trending somewhat negative on Saturday, InfoTrie Sentiment Analysis reports. The research group scores the sentiment of news coverage by analyzing more than six thousand blog and news sources in real time. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Avivagen earned a news impact score of -1.8 on InfoTrie's scale. They also gave media coverage about the company a news buzz of 0.0 out of 10, meaning that recent news coverage is extremely unlikely to have an impact on the company's share price in the next several days. View the latest news about Avivagen.

Who are some of Avivagen's key competitors?

What other stocks do shareholders of Avivagen own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Avivagen investors own include Snc-Lavalin Group (SNCAF) and ProMetic Life Sciences (PLI).

Who are Avivagen's key executives?

Avivagen's management team includes the following people:
  • Mr. G. F. Kym Anthony, Chairman, Interim CEO & Pres (Age 63)
  • Dr. Graham Burton, Co-Founder, Chief Scientific Officer & Director
  • Mr. Christopher Boland, Chief Financial Officer
  • Dr. Janusz Daroszewski, Co-Founder and Director of Product Devel. & Quality Assurance
  • Mr. Drew Basek, Director of Investor Relations

What is Avivagen's stock symbol?

Avivagen trades on the Canadian Venture Exchange (CVE) under the ticker symbol "VIV."

How do I buy shares of Avivagen?

Shares of VIV and other Canadian stocks can be purchased through online brokerage accounts that support trading on the Toronto Stock Exchange (TSX). Brokers that permit trading on the TSX include Fidelity, Interactive Brokers, PennTrade, and Charles Schwab.

What is Avivagen's stock price today?

One share of VIV stock can currently be purchased for approximately C$0.45.

How big of a company is Avivagen?

Avivagen has a market capitalization of C$18.74 million and generates C$628,772.00 in revenue each year. Avivagen employs 13 workers across the globe.

What is Avivagen's official website?

The official website for Avivagen is www.avivagen.com.

How can I contact Avivagen?

The company can be reached via phone at 613-949-8164.

This page was last updated on 7/11/2020 by MarketBeat.com Staff

30 Days of MarketBeat All Access for $1.00

Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools:

  • Best-in-Class Portfolio Monitoring

    View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.

  • Stock Ideas and Recommendations

    Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.

  • Advanced Stock Screeners and Research Tools

    Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your Risk-Free Trial Subscription Here

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.